Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Relatlimab
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Gastric Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Renal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Lung Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Uterine Corpus Cancer
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Uterine Cancer
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Prostate Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Rectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Skin Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Thyroid Gland Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Rogaratinib
Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
P2
CCC
(53)
Rogaratinib
Sarcoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Lymphoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Breast Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Cervical Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Colon Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Gastric Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Sapanisertib
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Showing 1976 to 2000 of 3,272 assets
Previous
Page 80 of 131
Next